Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have earned an average recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $30.9250.

Several research firms have recently commented on SNN. Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a research report on Monday, May 11th. Finally, Canaccord Genuity Group lowered their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th.

Smith & Nephew SNATS Trading Down 0.5%

Smith & Nephew SNATS stock opened at $30.52 on Friday. The company has a 50-day simple moving average of $31.30 and a 200-day simple moving average of $32.83. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. Smith & Nephew SNATS has a one year low of $28.40 and a one year high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, sell-side analysts forecast that Smith & Nephew SNATS will post 2.22 EPS for the current year.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several institutional investors have recently bought and sold shares of SNN. Garner Asset Management Corp acquired a new stake in Smith & Nephew SNATS in the fourth quarter worth about $27,000. Arax Advisory Partners lifted its holdings in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares during the period. Advisors Asset Management Inc. acquired a new stake in Smith & Nephew SNATS in the fourth quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Smith & Nephew SNATS in the third quarter worth about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Smith & Nephew SNATS in the fourth quarter worth about $43,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.